LTR Pharma secures US telehealth deal for ROXUS
LTR Pharma (ASX:LTP) has secured a foothold in the United States by executing a binding term sheet with Shed Holdings, an American direct-to-consumer telehealth platform.
The partnership establishes the first commercial route-to-market framework for LTR Pharma’s flagship erectile dysfunction treatment, ROXUS, within the world’s largest market for the condition.
Under the two-year exclusivity agreement, LTR Pharma retains its status as the product owner, intellectual property holder, and supplier.
Meanwhile, Shed will manage patient acquisition, telehealth services, and commercial infrastructure.
The primary distribution channel will be Mavrox, Shed's consumer-facing men's health platform. ROXUS is slated to be supplied via the U.S. Section 503A personalised medicine pathway through a designated U.S. 503A pharmacy fulfilment partner.
The framework sets a performance-based minimum commercial volume target of 150,000 ROXUS prescription units within the first 12 months of the commercial launch.
The target remains subject to supply logistics and the final execution of definitive agreements.
Distinguished by its rapid-acting intranasal format, ROXUS differentiates itself from traditional oral PDE5 inhibitors.
Both companies are now moving forward to finalise definitive agreements, initiate launch readiness activities, and complete integration with LTR Pharma’s US pharmacy fulfilment network to fast-track the product's highly anticipated American debut.
